分枝杆菌高通量药物筛选的分析开发
2024年10月25日
本研究开发了一种针对 脓肿分枝杆菌 的高通量筛选方法，使用荧光和发光快速评估细菌活力。该协议将与旨在筛选针对这种耐药细菌的新药的研究人员相关。
脓肿分枝杆菌对抗生素具有高度耐药性，仅与没有批准治疗方法的耐多药结核病相媲美。我们的研究重点是使用双报告基因菌株和 I3S 技术开发可扩展的药物筛选方案。这种方法旨在提高检测效率，加速发现有效、毒性较小的药物，并简化脓肿分枝杆菌的潜在治疗方法。
脓肿分枝杆菌感染的药物开发依赖于传统的耗时方法，例如菌落形成单位，这些方法需要大量劳动力，通量低，并且容易出现人为偏见。由于细菌的高耐药性，发现的命中较少。因此，为了找到新的治疗方法，必须对数千种化合物进行高通量筛选。
然而，传统方法使这变得不切实际。我们的方案使用内部开发的脓肿分枝杆菌双报告菌株，同时发射发光和荧光。它允许研究人员评估化合物的治疗效果，而无需添加任何额外的试剂或步骤，从而提高速度和可重复性。
此外，I3S Biosciences 筛选平台采用机器人自动化进行高通量筛选分析，无需任何人工干预即可处理 105 个微孔板，在提高疗效的同时减少错误。该方案能够更快、更可重复地筛选针对脓肿分枝杆菌的药物，有助于识别新的命中。它可以揭示关键的细菌靶标或化合物的官能团，从而深入了解成功和不成功的候选药物。
这种方法简化了指导未来研究的药物开发管道，并加速了对脓肿分枝杆菌的潜在命中物的识别。
概述
本研究使用双重报告基因菌株开发了一种高通量筛选黏毛结核分枝杆菌的方法。该方法提高了对这种耐药细菌的药物筛选效率。
关键研究组成部分
科学领域
- 微生物学
- 药物开发
- 高通量筛选
背景
- 黏毛结核分枝杆菌对抗生素高度耐药。
- 传统药物筛选方法耗时耗力且通量低。
- 高通量筛选对于识别新疗法至关重要。
- 现有方法容易出现人为偏差和低效率。
研究目的
- 开发一种可扩展的黏毛结核分枝杆菌药物筛选协议。
- 提高测试效率并加速药物发现。
- 简化这种病原体的药物开发流程。
使用的方法
- 利用双重报告基因菌株发射生物发光和荧光。
- 实施机器人自动化进行高通量分析。
- 在不需要额外步骤的情况下评估治疗效果。
- 使用高内容成像系统筛选化合物。
主要结果
- 几种化合物对黏毛结核分枝杆菌表现出不同水平的疗效。
- 克拉霉素显著降低了细菌活性。
- 机器人自动化提高了筛选效率并减少了错误。
- 获得了有关细菌靶点和化合物官能团的见解。
结论
- 开发的协议能够更快地筛选黏毛结核分枝杆菌的药物。
- 这种方法可以帮助识别新的治疗方向。
- 它简化了耐药感染的药物开发过程。
常见问题
Executive Industry Relevance
High-throughput drug screening against Mycobacterium abscessus addresses a critical bottleneck in anti-mycobacterial discovery, where traditional methods limit lead identification due to low throughput and high variability. The integration of double-reporter strains and robotic automation enhances predictive confidence and accelerates early-stage triage for drug-resistant pathogens. This capability is strategically positioned to impact portfolio prioritization and reduce attrition in anti-infective pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables rapid interrogation of compound efficacy against highly resistant mycobacteria.
- Supports functional target validation by providing dual readouts of bacterial viability.
- Facilitates mechanistic de-risking through quantitative, reproducible outputs.
- Improves predictive confidence for advancing early-stage anti-infective leads.
Screening & Assay Development
- Delivers standardized, reagent-free viability assays suitable for high-throughput workflows.
- Reduces assay variability and human bias via automation and dual-reporter readouts.
- Enables scalable screening of large compound libraries with minimal manual intervention.
- Prepares validated biological systems for downstream compound evaluation and hit confirmation.
Translational & Preclinical Research
- Aligns in vitro screening outputs with translational anti-mycobacterial research needs.
- Supports continuity from early discovery to preclinical candidate selection for resistant infections.
- Provides quantitative data to inform risk-adjusted advancement decisions in anti-infective portfolios.
Pipeline & Workflow Integration
This high-throughput assay integrates into the discovery-to-lead identification continuum, enabling efficient triage and prioritization of anti-mycobacterial compounds.
- Discovery Biology: Accelerates hypothesis testing and pathway clarification for drug-resistant mycobacteria.
- Screening: Provides reproducible, quantitative viability measurements for robust compound ranking.
- Analytics: Generates dual-mode readouts (luminescence and fluorescence) to support comparative analysis across conditions.
- Translational Research: Bridges early screening with preclinical validation for translationally relevant pathogens.
- Enterprise Reuse: Establishes a scalable, automation-ready platform for ongoing anti-infective discovery campaigns.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in anti-mycobacterial screening.
- Operational Value: Enhances standardization, reproducibility, and throughput via automation and dual-reporter technology.
- Strategic Value: Enables more informed go/no-go decisions and capital-efficient portfolio management.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of anti-infective candidates.
Implementation Considerations
- Requires expertise in high-content imaging and mycobacterial culture.
- Demands access to liquid-handling robotics and automated microscopy infrastructure.
- Necessitates cross-team standardization of assay protocols and data analysis pipelines.
- Adaptation to other mycobacterial or intracellular pathogen models may require reporter strain development.
- Throughput and scalability are contingent on automation and analytical capacity.
